Opportunities rise for LivaNova in CPBE market as Getinge surgical perfusion exit: GlobalData
GlobalData’s latest report reveals global CBPE market expected to grow at a CAGR of 1.2 per cent from $508.2 million in 2024 to $583.5 million in 2034
Swedish medtech company Getinge’s decision to exit the surgical perfusion business signals a strategic shift toward higher-growth areas like extracorporeal membrane oxygenation (ECMO). This move is set to benefit dominant players like LivaNova, which is well-positioned to capture the market share in the cardiopulmonary bypass equipment (CBPE) sector, which continues to show steady growth driven by technological advancements and the ageing population, says GlobalData.
GlobalData’s latest report, “Cardiopulmonary Bypass Equipment Market Size by Segments, Share, Regulatory, Reimbursement, Installed Base and Forecast to 2036,” reveals that the global CBPE market is expected to grow at a compound annual growth rate (CAGR) of 1.2 per cent from $508.2 million in 2024 to $583.5 million in 2034.
Aidan Robertson, Medical Analyst, GlobalData, comments, “Getinge’s decision to reallocate resources and focus on more lucrative areas like ECMO is unlikely to significantly impact the CPBE market. However, it may prove to be a beneficial strategy for the company, considering its struggles and low market share in this sector.”
However, the move is likely to favour major companies in the CPBE market such as LivaNova, which accounted for an estimated 50.3 per cent of the market share in 2024 and continues to make gains with Essenz heart lung machine. On the other hand, Getinge accounted for only 1.9 per cent of the CBPE market.
The demand for cardiopulmonary bypass products is likely to increase, driven by the growing ageing population and the resulting increase in cardiovascular diseases, alongside ongoing technological advancements in these devices. Some barriers to this growth may be the high cost of these procedures along with potential healthcare cost-cutting and reimbursement cuts. Despite these challenges, the CPBE market is expected to sustain stable growth.
Robertson concludes, “While Getinge’s decision to let go of the CPBE market appears to be the proper choice based on its past performance, GlobalData expects LivaNova to maintain its dominance in the steadily expanding CPBE market and take advantage of the opportunity created by Getinge’s exit.”
Edits made by EH News Bureau
- Advertisement -
